Photo of Dr. Larry H. Danziger

Larry H. Danziger


INST AFFL, Institute for Tuberculosis Research
Professor, Pharmacy Practice

Contact

Building & Room:

105

Address:

833 South Wood Street, Chicago, IL, 60612

Office Phone:

(312) 996-0892

Office Phone TTY:

(312) 413-1797

Email:

danziger@uic.edu

CV Link:

Larry H. Danziger

Office Phone:

(312) 355-0090

About

Dr. Danziger's research interests include surgical infectious disease, the unusual properties of
antimicrobial agents and pharmacological aspects of the patients with infectious diseases.

Selected Publications

  • Wenzler E, Meyer KM, Bleasdale SC, Sikka M, Mendes RE, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA. “Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects”. Antimicrobial agents and chemotherapy. 2020;64(2). doi:10.1128/AAC.02102-19.

  • Meyer KA, Deraedt MF, Harrington AT, Danziger LH, Wenzler E. “Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model”. International Journal of Antimicrobial Agents. 2019;54(2):197-201. doi:10.1016/j.ijantimicag.2019.04.010.

  • Biagi MJ, Wiederhold NP, Gibas C, Wickes BL, Lozano V, Bleasdale SC, Danziger LH. “Development of high-level echinocandin resistance in a patient with recurrent candida auris candidemia secondary to chronic candiduria”. Open Forum Infectious Diseases. 2019;6(7). doi:10.1093/ofid/ofz262.

  • Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E. “In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci”. Journal of Antimicrobial Chemotherapy. 2019;74(5):1300-1305. doi:10.1093/jac/dkz010.

  • Burgos RM, Biagi MJ, Rodvold KA, Danziger LH. “Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection”. Expert Opinion on Drug Metabolism and Toxicology. 2018;14(10):1007-1021. doi:10.1080/17425255.2018.1511702.

  • Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA. “Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants”. Antimicrobial Agents and Chemotherapy. 2018;62(8). doi:10.1128/AAC.00464-18.

  • Wenzler E, Bunnell KL, Danziger LH. “Clinical use of the polymyxins: the tale of the fox and the cat”. International Journal of Antimicrobial Agents. 2018;51(5):700-706. doi:10.1016/j.ijantimicag.2017.12.023.

  • Bunnell KL, Wenzler E, Harrington AT, Danziger LH. “Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae”. Diagnostic Microbiology and Infectious Disease. 2018;90(4):335-336. doi:10.1016/j.diagmicrobio.2017.12.007.

  • Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA. “Pharmacokinetics of telavancin at fixed doses in normal- body-weight and obese (classes I, II, and III) adult subjects”. Antimicrobial Agents and Chemotherapy. 2018;62(4). doi:10.1128/AAC.02475-17.

  • Chiampas TD, Kassamali Z, Justo JA, Danziger LH. “Opportunities and challenges in converting a pharmacy curriculum elective course from a live to an online teaching environment”. Pharmacy Education. 2018;18(1):50-53.

  • Guinta MM, Bunnell K, Harrington A, Bleasdale S, Danziger LH, Wenzler E. “Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile”. Annals of Clinical Microbiology and Antimicrobials. 2017;16(1). doi:10.1186/s12941-017-0252-7.

  • Wenzler E, Bunnell KL, Bleasdale SC, Benken ST, Danziger LH, Rodvold KA. “Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration”. Antimicrobial Agents and Chemotherapy. 2017;61(7). doi:10.1128/AAC.00464-17.

  • Horn KS, Danziger LH, Rodvold KA, Glowacki RC. “Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA”. Expert Opinion on Drug Metabolism and Toxicology. 2017;13(4):463-472. doi:10.1080/17425255.2017.1303481.

  • Meyer K, Santarossa M, Danziger LH, Wenzler E. “Compatibility of ceftazidime-avibactam, ceftolozane- tazobactam, and piperacillin-tazobactam with vancomycin in dextrose 5% in water”. Hospital Pharmacy. 2017;52(3):221-228. doi:10.1310/hpj5203-221.

  • Bunnell KL, Danziger LH, Johnson S. “Economic barriers in the treatment of clostridium difficile infection with oral vancomycin”. Open Forum Infectious Diseases. 2017;4(2). doi:10.1093/ofid/ofx078.

  • Danziger LH, Itokazu GS. “Clindamycin and lincomycin”. Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. 2017: 1468-1514

  • McConeghy KW, Soriano MM, Danziger LH. “A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile”. Pharmacotherapy. 2016;36(10):1095-1101. doi:10.1002/phar.1832.

  • El-Bietar J, Nelson A, Wallace G, Dandoy C, Jodele S, Myers KC, Teusink A, Lane A, Davies SM, Danziger-Isakov L. (2016). “RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplantation”. Bone Marrow Transplantation. Vol. 51. Issue 10. Page(s) 1382-1384. https://api.elsevier.com/content/abstract/scopus_id/84968649844

  • Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. (2016). “Inhaled antibiotics for gram-negative respiratory infections”. Clinical Microbiology Reviews. Vol. 29. Issue 3. Page(s) 581-632. https://api.elsevier.com/content/abstract/scopus_id/84969915305

  • Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled Antibiotics for Gram-Negative Respiratory Infections.. Clinical microbiology reviews. 2016;29(3):581-632. doi:10.1128/CMR.00101-15.

  • Wenzler E, Danziger LH. (2016). “Urinary tract infections: Resistance is futile”. Antimicrobial Agents and Chemotherapy. Vol. 60. Issue 4. Page(s) 2596-2597. https://api.elsevier.com/content/abstract/scopus_id/84963716040

  • Wenzler E, Danziger LH. (2016). Urinary Tract Infections: Resistance Is Futile.. Antimicrobial agents and chemotherapy. Vol. 60. Issue 4. Page(s) 2596-7.

  • Colton B, McConeghy KW, Schreckenberger PC, Danziger LH. “I.V. minocycline revisited for infections caused by multidrug-resistant organisms”. American Journal of Health-System Pharmacy. 2016;73(5):279-285. doi:10.2146/ajhp150290.

  • Colton B, McConeghy KW, Schreckenberger PC, Danziger LH. I.V. minocycline revisited for infections caused by multidrug-resistant organisms.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016;73(5):279-85. doi:10.2146/ajhp150290.

  • Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR, Jones RN. “Microbiological assessment of polymyxin B components tested alone and in combination”. Antimicrobial Agents and Chemotherapy. 2015;59(12):7823-7825. doi:10.1128/AAC.01021-15.

  • Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR, Jones RN. Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.. Antimicrobial agents and chemotherapy. 2015;59(12):7823-5. doi:10.1128/AAC.01021-15.

  • Wenzler E, Dickson W, Vibhakar S, Adeyemi OM, Danziger LH. (2015). Hepatitis C Management and the Infectious Diseases Pharmacist.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Vol. 61. Issue 7. Page(s) 1201-2.

  • Justo JA, Mayer SM, Pai MP, Soriano MM, Danziger LH, Novak RM, Rodvold KA. “Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects”. Antimicrobial Agents and Chemotherapy. 2015;59(7):3956-3965. doi:10.1128/AAC.00498-15.

  • Wenzler E, Mulugeta SG, Danziger LH. (2015). “The antimicrobial stewardship approach to combating Clostridium difficile”. Antibiotics. Vol. 4. Issue 2. Page(s) 198-215. https://api.elsevier.com/content/abstract/scopus_id/85019824926

  • Justo JA, Mayer SM, Pai MP, , Danziger LH, Novak RM, Rodvold KA. Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects.. Antimicrobial agents and chemotherapy. 2015;. doi:10.1128/AAC.00498-15.

  • , Rodvold KA, Danziger LH. (2015). Editorial commentary: improving prescribers to advance antimicrobial stewardship.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Vol. 60. Issue 8. Page(s) 1259-61.

  • Kassamali Z, Jain R, Danziger LH. (2015). “An Update on the arsenal for multidrug-resistant Acinetobacter infections: Polymyxin antibiotics”. International Journal of Infectious Diseases. Vol. 30. Page(s) 125-132. https://api.elsevier.com/content/abstract/scopus_id/84918556534

  • Kassamali Z, Jain R, Danziger LH. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2015;30:125-32. doi:10.1016/j.ijid.2014.10.014.

  • Wenzler E, Rodvold KA, Danziger LH. (2015). “Editorial commentary: Improving prescribers to advance antimicrobial stewardship”. Clinical Infectious Diseases. Vol. 60. Issue 8. Page(s) 1259-1261. https://api.elsevier.com/content/abstract/scopus_id/84926625679

  • Wenzler E, Dickson W, Vibhakar SR, Adeyemi OM, Danziger LH. (2015). “Hepatitis C Management and the Infectious Diseases Pharmacist”. Clinical Infectious Diseases. Vol. 61. Issue 7. Page(s) 1201-1202. https://api.elsevier.com/content/abstract/scopus_id/84942088761

  • Kassamali Z, Danziger LH. “To B or not to B, that is the question: Is it time to replace colistin with polymyxin B?”. Pharmacotherapy. 2015;35(1):17-21. doi:10.1002/phar.1510.

  • Merker A, Danziger LH, Rodvold KA, Glowacki RC. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.. Expert opinion on drug metabolism & toxicology. 2014;10(12):1741-50. doi:10.1517/17425255.2014.972932.

  • , Danziger LH, Gerding DN, Johnson S. Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies.. Open forum infectious diseases. 2014;1(2):ofu069. doi:10.1093/ofid/ofu069.

  • Suda K, Regen SM, Lee TA, Easterling JL, Hunkler RJ, Danziger LH. Outpatient influenza antiviral prescription trends with influenza-like illness in the USA, 2008-2010.. International journal of antimicrobial agents. 2014;43(3):279-83. doi:10.1016/j.ijantimicag.2013.10.025.

  • Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. (2013). Reply to Nation et al.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Vol. 57. Issue 11. Page(s) 1657-8.

  • Justo JA, Danziger LH, Gotfried MH. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis.. Therapeutic advances in respiratory disease. 2013;7(5):272-87. doi:10.1177/1753465813487412.

  • Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. Polymyxins: wisdom does not always come with age.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;57(6):877-83. doi:10.1093/cid/cit367.

  • , Liao S, Danziger LH. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.. Expert review of anti-infective therapy. 2013;11(8):767-76. doi:10.1586/14787210.2013.814767.

  • Kassamali Z, Danziger LH, Glowacki RC, Schwartz DN. How low can you go? Use of low- and standard-dose liposomal amphotericin B for treatment of invasive fungal infections.. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2013;17(8):e615-20. doi:10.1016/j.ijid.2013.01.015.

  • , Kassamali Z, Danziger LH. Behind closed doors: medication storage and disposal in the home.. The Annals of pharmacotherapy. 2013;47(4):482-9. doi:10.1345/aph.1R706.

  • Suda K, Hicks LA, Roberts RM, Hunkler RJ, Danziger LH. A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009.. The Journal of antimicrobial chemotherapy. 2013;68(3):715-8. doi:10.1093/jac/dks445.

  • Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial.. The Annals of pharmacotherapy. 2007;41(6):965-72. doi:10.1345/aph.1H543.

  • Joseph JM, Jain R, Danziger LH. Micafungin: a new echinocandin antifungal.. Pharmacotherapy. 2007;27(1):53-67. doi:10.1592/phco.27.1.53.

  • Jain R, Schriever CA, Danziger LH, Cho SH, Rubinstein I. The IS6110 repetitive DNA element of Mycobacterium tuberculosis is not detected in exhaled breath condensate of patients with active pulmonary tuberculosis.. Respiration; international review of thoracic diseases. 2007;74(3):329-33. doi:10.1159/000101786.

  • Itokazu GS, Schwartz DN, Garey KW, Rodvold KA, Danziger LH, Weinstein RA. Pharmacists’ perceptions of the effectiveness of antimicrobial control programs.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2006;63(24):2504-8. doi:10.2146/ajhp060131.

  • Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.. Diagnostic microbiology and infectious disease. 2006;55(4):303-9. doi:10.1016/j.diagmicrobio.2006.06.013.

  • Schriever CA, Fernández C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2005;62(11):1145-58.

  • Suda K, Garey KW, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone.. Pharmacy world & science : PWS. 2005;27(2):81-2.

  • Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases.. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2005;24(1):31-40. doi:10.1007/s10096-004-1253-y.

  • Lodise TP, Jr B, Lomaestro KA, Rodvold LH, Danziger GL, Drusano . Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.. Antimicrobial agents and chemotherapy. 2004;48(12):4718-24. doi:10.1128/AAC.48.12.4718-4724.2004.

  • Sprandel KA, Schriever CA, , Quinn JP, Gotfried MH, Hackett S, Graham MB, Danziger LH, Rodvold KA. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.. Antimicrobial agents and chemotherapy. 2004;48(12):4597-605. doi:10.1128/AAC.48.12.4597-4605.2004.

  • Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.. The Annals of pharmacotherapy. 2004;38(9):1449-59. doi:10.1345/aph.1D592.

  • Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA, Danziger LH. Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.. Current therapeutic research, clinical and experimental. 2004;65(1):1-12. doi:10.1016/S0011-393X(04)90000-8.

  • Gunderson SM, Hayes RA, Quinn JP, Danziger LH. In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.. Antimicrobial agents and chemotherapy. 2004;48(1):203-8.

  • Garey KW, , Robbins RA, Danziger LH, Rubinstein I. Markers of inflammation in exhaled breath condensate of young healthy smokers.. Chest. 2004;125(1):22-6.

  • Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview.. Current pharmaceutical design. 2004;10(25):3045-53.

  • Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects.. The Journal of antimicrobial chemotherapy. 2003;52(3):450-6. doi:10.1093/jac/dkg355.

  • Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.. Antimicrobial agents and chemotherapy. 2003;47(8):2450-7.

  • Cannon JP, Fiscella R, Pattharachayakul S, Garey KW, De Alba F, Piscitelli S, Edward DP, Danziger LH. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.. Investigative ophthalmology & visual science. 2003;44(5):2112-7.

  • , Prause JL, Danziger LH, . In vitro bactericidal activities of ABT-773 against ermB strains of Streptococcus pneumoniae.. Antimicrobial agents and chemotherapy. 2003;47(3):1132-4.

  • , Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.. JAMA. 2003;289(7):885-8.

  • Garey KW, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases.. Chest. 2003;123(1):261-5.

  • , Jung R, Danziger LH, . In vitro bactericidal activity of ABT-773 versus four other agents against Streptococcus pneumoniae and Haemophilus influenzae.. International journal of antimicrobial agents. 2002;20(5):395-8.

  • Itokazu GS, Fischer JH, Manitpisitkul P, Hariharan R, Danziger LH. Lack of effect of nizatidine-induced elevation of gastric pH on the oral bioavailability of dapsone in healthy volunteers.. Pharmacotherapy. 2002;22(11):1420-5.

  • Max BE, Itokazu GS, Danziger LH, Weinstein RA. Assessing unit dose system discrepancies.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2002;59(9):856-8.

  • Jung R, Danziger LH, . Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila.. The Journal of antimicrobial chemotherapy. 2002;49(5):857-61.

  • Drusano GL, Preston SL, Gotfried MH, Danziger LH, Rodvold KA. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.. Antimicrobial agents and chemotherapy. 2002;46(2):586-9.

  • , Prause JL, Danziger LH, . Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.. Antimicrobial agents and chemotherapy. 2001;45(12):3613-5. doi:10.1128/AAC.45.12.3613-3615.2001.

  • Lesch CA, Itokazu GS, Danziger LH, Weinstein RA. Multi-hospital analysis of antimicrobial usage and resistance trends.. Diagnostic microbiology and infectious disease. 2001;41(3):149-54.

  • Pai MP, , Danziger LH. Antimicrobial-coated/bonded and -impregnated intravascular catheters.. The Annals of pharmacotherapy. 2001;35(10):1255-63.

  • Bearden DT, Danziger LH. Mechanism of action of and resistance to quinolones.. Pharmacotherapy. 2001;21(10 Pt 2):224S-232S.

  • Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.. Pharmacotherapy. 2001;21(9):1107-14.

  • Mutlu GM, Garey KW, Robbins RA, Danziger LH, Rubinstein I. Collection and analysis of exhaled breath condensate in humans.. American journal of respiratory and critical care medicine. 2001;164(5):731-7. doi:10.1164/ajrccm.164.5.2101032.

  • Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.. Chest. 2001;119(4):1114-22.

  • Donald PR, Sirgel FA, Kanyok TP, Danziger LH, Venter A, Botha FJ, Parkin DP, Seifart HI, Van De Wal BW, Maritz JS, Mitchison DA. Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis.. Antimicrobial agents and chemotherapy. 2000;44(12):3285-7.

  • Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.. Chest. 2000;118(6):1826-7.

  • Delgado G, Jr , DT, Bearden LH, Danziger . Quinupristin-dalfopristin: an overview.. Pharmacotherapy. 2000;20(12):1469-85.

  • , Prause JL, , Boyea N, Hackleman JM, Danziger LH. In vitro activities of a new ketolide, ABT-773, alone and in combination with amoxicillin, metronidazole, or tetracycline against Helicobacter pylori.. Antimicrobial agents and chemotherapy. 2000;44(9):2518-20.

  • Jung R, Messick CR, , Tesoro EP, Losendahl KJ, Schriever CA, Danziger LH. Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes.. Antimicrobial agents and chemotherapy. 2000;44(3):778-9.

  • , Diaz-Linares M, Garey KW, Woodward JG, Ryu S, Danziger LH. Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.. Antimicrobial agents and chemotherapy. 1999;43(10):2547-9.

  • Meyer JM, Ryu S, , Kanyok TP, Danziger LH. In-vitro synergy of paromomycin with metronidazole alone or metronidazole plus hydroxymetronidazole against Helicobacter pylori.. The Journal of antimicrobial chemotherapy. 1999;43(3):403-6.

  • Messick CR, Mamdani M, McNicholl IR, Danziger LH, Rodvold KA, Condon RE, Walker AP, Edmiston CE, Jr . Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections.. Pharmacotherapy. 1998;18(1):175-83.

  • Rodvold KA, Danziger LH, Quinn JP. Single daily doses of aminoglycosides.. Lancet. 1997;350(9089):1412. doi:10.1016/S0140-6736(97)22046-5.

  • , Martin SJ, Chen C, Schreckenberger PC, Danziger LH. Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.. Journal of clinical microbiology. 1997;35(11):3004-6.

  • Martin SJ, , Chen C, Schreckenberger PC, Danziger LH. In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin.. Diagnostic microbiology and infectious disease. 1997;29(3):167-71.

  • Occhipinti DJ, , Schoonover LL, Rypins EB, Danziger LH, Rodvold KA. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.. Antimicrobial agents and chemotherapy. 1997;41(11):2511-7.

  • Meyer JM, Ryu S, , Danziger LH. In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.. Antimicrobial agents and chemotherapy. 1997;41(7):1607-8.

  • Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.. Antimicrobial agents and chemotherapy. 1997;41(6):1399-402.

  • Kanyok TP, Killian AD, Rodvold KA, Danziger LH. Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects.. Antimicrobial agents and chemotherapy. 1997;41(5):982-6.

  • Messick CR, Danziger LH. Therapeutic modalities for mechanical cleansing of the colon.. Journal of the American Pharmaceutical Association (Washington,D.C. : 1996). 1996;NS36(7):439-42.

  • Martin SJ, , Chen C, Schreckenberger P, Danziger LH. In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella.. Antimicrobial agents and chemotherapy. 1996;40(6):1419-21.

  • Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies.. Pharmacotherapy. 1995;15(3):279-91.

  • Schoonover LL, Occhipinti DJ, Rodvold KA, Danziger LH. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.. The Annals of pharmacotherapy. 1995;29(5):501-14.

  • Danziger LH, . Bacterial resistance to beta-lactam antibiotics.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 1995;52(6 Suppl 2):S3-8.

  • , Piscitelli SC, Schreckenberger PC, Danziger LH. In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp.. Antimicrobial agents and chemotherapy. 1994;38(9):2106-10.

  • Martin SJ, Danziger LH. Continuous infusion of loop diuretics in the critically ill: a review of the literature.. Critical care medicine. 1994;22(8):1323-9.

  • Gubbins PO, Occhipinti DJ, Danziger LH. Surveillance of treated and untreated funguria in a university hospital.. Pharmacotherapy. 1994;14(4):463-70.

  • Occhipinti DJ, Gubbins PO, Schreckenberger P, Danziger LH. Frequency, pathogenicity and microbiologic outcome of non-Candida albicans candiduria.. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 1994;13(6):459-67.

  • Danziger LH, Piscitelli SC, Occhipinti DJ, Resnick DJ, Rodvold KA. Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.. The Annals of pharmacotherapy. 1994;28(6):703-7.

  • Danziger LH, Schoonover LL, Kale P, Resnick DJ. Eikenella corrodens as an intra-abdominal pathogen.. The American surgeon. 1994;60(4):296-9.

  • Fish DN, Gotfried MH, Danziger LH, Rodvold KA. Penetration of clarithromycin into lung tissues from patients undergoing lung resection.. Antimicrobial agents and chemotherapy. 1994;38(4):876-8.

  • Danziger LH, Martin SJ, Blum RA. Central nervous system toxicity associated with meperidine use in hepatic disease.. Pharmacotherapy. 1994;14(2):235-8.

  • Kayok TP, Reddy MV, Chinnaswamy J, Danziger LH, Gangadharam PR. Activity of aminosidine (paromomycin) for Mycobacterium tuberculosis and Mycobacterium avium.. The Journal of antimicrobial chemotherapy. 1994;33(2):323-7.

  • Kanyok TP, Reddy MV, Chinnaswamy J, Danziger LH, Gangadharam PR. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains.. Antimicrobial agents and chemotherapy. 1994;38(2):170-3.

  • Piscitelli SC, Hoffman H, Danziger LH. Oral antibiotic usage in hospitalized patients.. Hospital pharmacy. 1994;29(2):100-1, 104-5, 120.

  • Piscitelli SC, Occhipinti DJ, Danziger LH, Hill C, West DP, Fischer JH. Therapeutic monitoring and pharmacist intervention in a Hansen’s disease clinic.. The Annals of pharmacotherapy. 1993;27(12):1526-31.

  • Danziger LH, Kanyok TP, Novak RM. Treatment of cryptosporidial diarrhea in an AIDS patient with paromomycin.. The Annals of pharmacotherapy. 1993;27(12):1460-2.

  • Fish DN, Danziger LH. Neglected pathogens: bacterial infections in persons with human immunodeficiency virus infection. A review of the literature (2).. Pharmacotherapy. 1993;13(6):543-63.

  • Danziger LH. (1993). Prophylaxis with aztreonam plus metronidazole during appendectomy.. American journal of hospital pharmacy. Vol. 50. Issue 11. Page(s) 2314-5.

  • Danziger LH. (1993). Prophylaxis with aztreonam plus metronidazole during appendectomy.. Clinical pharmacy. Vol. 12. Issue 11. Page(s) 803.

  • Occhipinti DJ, Schoonover LL, Danziger LH. (1993). Bladder irrigation with amphotericin B for treatment of patients with candiduria.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Vol. 17. Issue 4. Page(s) 812-3.

  • Fish DN, Danziger LH. Neglected pathogens: bacterial infections in persons with human immunodeficiency virus infection. A review of the literature (1).. Pharmacotherapy. 1993;13(5):415-39.

  • Gubbins PO, Piscitelli SC, Danziger LH. Urinary tract infections caused by Candida species.. The Journal of practical nursing. 1993;43(2):25-34.

  • Gubbins PO, Piscitelli SC, Danziger LH. Candidal urinary tract infections: a comprehensive review of their diagnosis and management.. Pharmacotherapy. 1993;13(2):110-27.

  • Piscitelli SC, Danziger LH, Hill C, Slajchert AA, West DP, Fischer JH. Effectiveness of a dapsone compliance program in leprosy.. International journal of dermatology. 1993;32(3):206-9.

  • , Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.. Clinical pharmacokinetics. 1992;23(5):328-64. doi:10.2165/00003088-199223050-00002.

  • Fish DN, Hoffman HM, Danziger LH. Antibiotic-impregnated cement use in U.S. hospitals.. American journal of hospital pharmacy. 1992;49(10):2469-74.

  • Wilkes L, Danziger LH, Rodvold KA. Phenobarbital pharmacokinetics in obesity. A case report.. Clinical pharmacokinetics. 1992;22(6):481-4. doi:10.2165/00003088-199222060-00006.

  • Fish DN, Piscitelli SC, Danziger LH. (1992). Quinolone resistance: an alternative perspective.. Archives of internal medicine. Vol. 152. Issue 6. Page(s) 1329-30.

  • Piscitelli SC, Shwed J, Schreckenberger P, Danziger LH. Streptococcus milleri group: renewed interest in an elusive pathogen.. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 1992;11(6):491-8.

  • Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics.. Clinical pharmacy. 1992;11(2):137-52.

  • Occhipinti DJ, Itokazu GS, Danziger LH. Selective decontamination of the digestive tract as an infection-control measure in intensive care unit patients.. Pharmacotherapy. 1992;12(6 Pt 2):50S-63S.

  • Stellato TA, Gordon NH, Danziger LH. (1991). Addition of parenteral cefoxitin to regimen of oral antibiotics for elective colorectal operations.. Annals of surgery. Vol. 213. Issue 4. Page(s) 375-6.

  • Shwed JA, Danziger LH, , Rodvold KA. A comparative evaluation of the safety and efficacy of cefotetan and cefoxitin in surgical prophylaxis.. DICP : the annals of pharmacotherapy. 1991;25(1):10-3.

  • Itokazu GS, Danziger LH. Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy.. Pharmacotherapy. 1991;11(5):382-414.

  • Stellato TA, Danziger LH, Gordon N, Hau T, Hull CC, Zollinger RM, Jr JM, Shuck . Antibiotics in elective colon surgery. A randomized trial of oral, systemic, and oral/systemic antibiotics for prophylaxis.. The American surgeon. 1990;56(4):251-4.

  • Danziger LH, Furmaga KM, Rodvold KA, Bombeck CT, Fischer JH. Nizatidine suppression of basal gastric acid output: a comparison of two intravenous dosage regimens.. Journal of clinical pharmacology. 1989;29(10):946-52.

  • Stellato TA, Danziger LH, Burkons D. Fetal salvage with maternal total parenteral nutrition: the pregnant mother as her own control.. JPEN. Journal of parenteral and enteral nutrition. 1988;12(4):412-3.

  • Stellato TA, Danziger LH, Hau T, Gauderer MW, Ferron JL, Gordon N. Moxalactam vs tobramycin-clindamycin. A randomized trial in secondary peritonitis.. Archives of surgery (Chicago, Ill. : 1960). 1988;123(6):714-7.

  • Stellato TA, Townsend MC, Gordon N, Danziger LH, Galloway P, Hawkins NL, Fry DE. Effects of muramyl dipeptide and core body temperature on peritoneal bacterial clearance.. Archives of surgery (Chicago, Ill. : 1960). 1988;123(4):465-9.

  • Danziger LH, Creger RJ, Shwed JA, Stellato TA, Hau T. Randomized trial of imipenem-cilastatin versus gentamicin plus clindamycin in the treatment of polymicrobial infections.. Pharmacotherapy. 1988;8(6):315-8.

  • Danziger LH. Controversies in antimicrobial therapy: innovative methods of administration.. American journal of hospital pharmacy. 1986;43(3):646-52.

  • Creger RJ, Cowan RI, Nearman HS, Blumer JL, Selman WR, Danziger LH. Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients.. Antimicrobial agents and chemotherapy. 1985;28(6):839-41.

  • Stellato TA, Danziger LH, Nearman HS, Creger RJ. Inadvertent intravenous administration of enteral diet.. JPEN. Journal of parenteral and enteral nutrition. 1984;8(4):453-5.

  • Hanus PM, Danziger LH. Treatment of chronic bacterial prostatitis.. Clinical pharmacy. 1984;3(1):49-55.

  • Glazier HS, Danziger LH, Green JA. (1983). Clinical pharmacists and the undereducated physician.. The New England journal of medicine. Vol. 309. Issue 20. Page(s) 1257-8.

  • Danziger LH, Horn JR. Disopyramide-induced urinary retention. Report of nine cases and review of the literature.. Archives of internal medicine. 1983;143(9):1683-86.

  • Hau T, Nishikawa R, Danziger LH. Antibiotics in surgery.. Surgery annual. 1983;15:177-205.

  • Danziger LH, Cowan D. Interdisciplinary grand rounds. Legal consequences of prescribing an approved drug for a non-approved use: cimetidine; a case in point.. Health matrix. 1983;1(1):51-7.

  • Stromberg BV, Davis RJ, Danziger LH. Relationship of serum transferrin to total iron binding capacity for nutritional assessment.. JPEN. Journal of parenteral and enteral nutrition. 1982;6(5):392-4.

  • Horn JR, Danziger LH, Davis RJ. Warfarin-induced skin necrosis: report of four cases.. American journal of hospital pharmacy. 1981;38(11):1763-8.

    • Education

  • PharmD, , University of Cincinnati, Cincinnati, OH

  • , , VA Hospital Cincinnati, Cincinnati, Ohio

  • BS, Pharmacy, University of Illinois at Chicago, Chicago, IL

  • BA, History, University of Illinois, Urbana, IL